Today's Rundown Gilead shares slip as a 2nd remdesivir COVID-19 trial halted in China WHO tasks ex-GSK CEO Witty with hastening COVID-19 vaccine R&D Lawrence lands Cardurion CEO job after helping ArQule to Merck buyout Moma Therapeutics aims at molecular machines with $86M raise Novartis, TScan unite on TCR treatments for solid tumors Leo Pharma pens Oneness Biotech, Microbio Shanghai pact for skin and asthma drug Boehringer Ingelheim taps Insilico Medicine for AI drug target collaboration Can a popular class of diabetes drugs that includes Merck's Januvia help treat COVID-19? Featured Story | | | Wednesday, April 15, 2020 After having to halt enrollment in its severe COVID-19 trial due to a lack of patients, a second test of Gilead’s old Ebola drug remdesivir has befallen the same fate, this time in patients with a milder form of the disease. |
|
|---|
|
Top Stories Wednesday, April 15, 2020 The World Health Organization (WHO) has tasked ex-GlaxoSmithKline CEO Andrew Witty with helping accelerate development of a COVID-19 vaccine. Witty is taking a leave of absence from his job at UnitedHealth Group until around the end of the year to co-lead the WHO initiative. Wednesday, April 15, 2020 Peter Lawrence has taken up the CEO job at Cardurion Pharmaceuticals, a Takeda-partnered biotech that is moving a heart failure drug through the clinic. Lawrence landed the gig on the strength of a 14-year spell at ArQule that culminated in a $2.7 billion takeover by Merck. Wednesday, April 15, 2020 Moma Therapeutics wants to crack a new type of drug target wide open. The company snagged $86 million from the likes of Third Rock Ventures to systematically go after molecular machines, a family of more than 400 enzymes that others have only stumbled upon by chance. Wednesday, April 15, 2020 Last summer, Novartis pitched in to a $48 million venture round for a cell therapy startup called TScan Therapeutics. Now, the Swiss pharma is back for more: In a deal worth $30 million upfront, the duo is on the hunt for targets that could lead to new T-cell receptor therapies for solid cancers. Wednesday, April 15, 2020 Leo Pharma is paying $40 million upfront and $530 million in biobucks to license a midstage experimental eczema and asthma drug. Tuesday, April 14, 2020 Boehringer Ingelheim has tapped artificial intelligence maven Insilico Medicine to help identify new drug targets through its internal Research Beyond Borders initiative, which is tasked with forming new collaborations outside of the company’s traditional therapeutic areas and geographies. Wednesday, April 15, 2020 Scientists are attempting to repurpose existing drugs as a quick way to tackle COVID-19. Among them is a University of Miami researcher who has pointed to previous studies of other coronaviruses in suggesting DPP-4 inhibitors used to treat diabetes might help. Resources Sponsored by: BBK Worldwide Leverage strategic solutions to respond to immediate challenges to patient and site engagement from COVID-19, and learn to maximize the FDA guidance on the conduct of clinical trials during a pandemic. Sponsored by: Oracle Health Sciences The research conducted here is to help understand and solve the top challenges in clinical operations, to remove barriers that are slowing down our ability to bring new drugs to market as quickly as possible to patients waiting in need. Sponsored by: Clinical Ink This white paper includes a Phase III case study and discusses BYOD advantages and misconceptions, regulatory, copyright, and equivalency considerations. Sponsored by: Research Solutions Turn your drug failures into competitive advantage. Sponsored by: ICON How will US payers evaluate and manage digital therapeutics? Get insights and recommendations on successful market access considerations. Sponsored by: Epsilon Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing. Sponsored by: Copyright Clearance Center Despite advances in content aggregation and search, silos still limit the free flow of data and analytics. So, what can be done, and how can you get more value from the data you already have? Sponsored by: Applied BioMath Learn how we used a tiered model-based approach of a bispecific antibody to appropriately cover multiple antigen pairs to help teams with informed antibody design, prioritization of experiments, and triaging of challenging antigen pairs Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Outer Edge Technology To survive in these challenging conditions, companies need to promptly address business continuity issues - especially the remote delivery of data and voice solutions. See how Outer Edge can help. Sponsored by: Patheon, by Thermo Fisher Scientific Poorly soluble molecules hindering your workflow? Sponsored by: eClinical Solutions Key findings from the 2019 Life Sciences Data & Analytics Survey conducted by the Tufts Center for the Study of Drug Development will be unveiled during this live webinar led by industry expert and study lead, Ken Getz, Director of Sponsored Programs and Associate Professor. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Clarify Health Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. BioBasics 201: Targeted Biologics for the Non-Scientist June 16-17, 2020 | Boston, MA Medical Affairs Strategic Summit (MASS) East April 14-16, 2020 | New Brunswick, NJ BioBasics 101: The Biology of Biotech April 16-17, 2020 | Philadelphia, PA Drug Development Immersion April 23-24, 2020 | Boston, MA PEGS Boston – The Essential Protein Engineering & Cell Therapy Summit May 4-8, 2020 | Boston, MA 8-week Online Courses in Life Sciences Law and Compliance Virtual Course | May 31st, 2020 European Healthcare Compliance Certificate Program June 2-5, 2020 | Paris, France BIO 2020 Now Fully Virtual: Announcing BIO Digital June 8-11, 2020 | Virtual Event Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. | 